Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hepatitis A infection is typically transmitted by the fecal-oral route. Symptomatic infection is highly dependent on the age of the patient and usually follows a self-limited course. Once diagnosed, clinical and biochemical follow-up in the outpatient setting is generally appropriate. Treatment aims are to achieve symptomatic relief and to maintain adequate hydration and caloric intake. In patients with more severe disease, hospitalization may be needed to accomplish aggressive symptomatic therapy and close monitoring of liver function tests and mental status. Prompt evaluation for liver transplantation is appropriate in the rare case where fulminant liver failure develops. Given the absence of specific therapy for hepatitis A virus infection, the most important health care intervention is prevention of infection and/or transmission, which can be accomplished with the safe and effective use of immune globulin and commercially available vaccines.
- Fiore A: Hepatitis A transmitted by food. CID 2004, 38: 705–715. Excellent manuscript that details the epidemiology, clinical characteristics, diagnosis, and prevention of hepatitis A infection. CrossRef
- Lemon SM: Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin Chem 1997, 43: 1494–1499.
- Bell BP, Feinstone SM: Hepatitis A vaccine. In Vaccines, edn 4. Edited by Plotkin SA, Orenstein WA. Philadelphia: Saunders 2004: 269–297.
- Centers for Disease Control and Prevention: Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999, 48(RR-12): 1–37.
- Bell BP, Shapiro CN, Alter MJ, et al.: The diverse patterns of hepatitis A epidemiology in the United States. J Infect Dis 1998, 178: 1579–1584. CrossRef
- Kemmer NM, Miskovsky EP: Hepatitis A. Inf Dis Clin Norht Am 2000, 14: 605–615. CrossRef
- Ryder SD, Beckingham IJ: ABC of diseases of liver, pancreas, and biliary system: acute hepatitis. BMJ 2001, 322: 151–153. CrossRef
- Keeffe EB: Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995, 90: 201–205.
- Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338: 286–290. CrossRef
- Jones AM, Warken K, Tyring SK: The cutaneous manifestations of viral hepatitis. Dermatol Clin 2002, 20: 233–247. CrossRef
- Ozaras R, Mert A, Yilmaz MH, et al.: Acute viral cholecystitis due to hepatitis A virus infection. J Clin Gastroenterol 2003, 37: 79–81. CrossRef
- Katz JP, Lichtenstein GR: Rheumatologic manifestations of gastrointestinal diseases. Gastroenterol Clin North Am 1998, 27: 533–562. CrossRef
- Shrier LA, Karpen SJ, McEvoy C: Acute pancreatitis associated with acute hepatitis A in a young child. J Pediatr 1995, 126: 57–59. CrossRef
- Bornstein JD, Byrd DE, Trotter JF: Relapsing hepatitis A: a case report and review of the literature. J Clin Gastroenterol 1999, 28: 355–6. CrossRef
- Schiff ER: Atypical clinical manifestations of hepatitis A. Vaccine 1992, 10: S18–20. CrossRef
- Centers for Disease Control and Prevention. Hepatitis surveillance. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service; 1996. [Report no. 56].
- Mosley JW, Reisler DM, Brachott D, et al.: Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis A. Am J Epidemiol 1968, 87: 539–550.
- Ellis EF, Henney CS: Adverse reactions following administration of human gamma globulin. J Allergy Clin Immunol 1969, 43: 45–54.
- Centers for Disease Control and Prevention: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP); 1994, 43 (RR-1)
- Craig AS, Schaffner W: Clinical practice. Prevention of hepatitis A with the hepatitis A vaccine. N Eng J Med 2004, 350: 476–481. This manuscript reviews the implementation of HAV vaccination from a clinical perspective and provides a concise background on the epidemiology and clinical features of HAV infection. CrossRef
- Clemens R, Safary A, Hepburn A, et al.: Clinical experience with an inactivated hepatitis A vaccine. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995, 171: S44–9.
- McMahon BJ, Williams J, Bulkow L, et al.: Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and native and non-native adults. J Infect Dis 1995, 171: 676–679.
- Werzberger A, Mensch B, Kuter B, et al.: A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992, 327: 453–457. CrossRef
- Innis BL, Snitbhan R, Kunasol P, et al.: Protection by an inactivated vaccine. JAMA 1994, 271: 1328–34. CrossRef
- Van Damme P, Banatvala J, Fay O, et al.: International Consensus Group on Hepatitis A Virus Immunity. Hepatitis A booster vaccination: is there a need? Lancet 2003, 362: 1065–1071. CrossRef
- Wiens BL, Bohidar NR, Pigeon JG, et al.: Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996, 49: 235–241. CrossRef
- Wiedermann G, Kundi M, Ambrosch F, et al.: Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 1997, 15: 612–615. CrossRef
- Keeffe EB, Iwarson S, McMahon BJ, et al.: Safety and Immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998, 27: 881–886. CrossRef
- Dumot JA, Barnes DS, Younossi Z, et al.: Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999, 94: 1601–1604. CrossRef
- Chalasani N, Smallwood G, Halcomb J, et al.: Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998, 4: 128–132. CrossRef
- Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB: Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001, 34: 28–31. CrossRef
- Das A: An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999, 29: 548–552. CrossRef
- Beutels P, Edmunds WJ, Antonanzas F, et al.: Viral Hepatitis Prevention Board. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002, 20: 1–7. CrossRef
- Deneke MG, Arguedas MR: Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs. Expert Rev Vaccines 2003, 2: 661–672. Provides a detailed background on the economic aspects of vaccination programs for hepatitis A vaccine in various populations and patient groups. CrossRef
- Hepatitis A
Current Treatment Options in Gastroenterology
Volume 7, Issue 6 , pp 443-450
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links